HIKMA PHAR.SP.ADR/2LS-,10 ADR

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2026, HIKMA PHAR.SP.ADR/2LS-,10 ADR has already paid €1.49 in dividends. The last payout was in September.

Financials

In the last quarter, HIKMA PHAR.SP.ADR/2LS-,10 ADR had revenue of €1.51bn and net profit of €195.36m

(EUR)	June 2026	YoY
Revenue	1.51bn	-
Gross profit	637.76m	-
Net profit	195.36m	-
EBITDA	422.25m	-

Fundamentals

Metric	Value
Market capitalization	€4.15bn
Number of shares	104.74m
52-week high/low	€44.02 - €28.39
Dividend yield	3.33%
Dividends TTM	€1.48
Beta	0.66
P/E ratio	12.52
PEG ratio	-0.13
P/B ratio	1.87
P/S ratio	1.36

Company profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.